BOLAJI BOLARINWA: Open Payments
NPI 1104476381 · MARLTON, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$819 in 49 payments from 10 companies in 2025. Trend: 2023 $702 · 2024 $1,036 · 2025 $819
Food & beverage: $819
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $166 |
| Neurocrine BioSciences, Inc. | 6 | $125 |
| Vanda Pharmaceuticals Inc. | 5 | $93 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $91 |
| Alkermes, Inc. | 5 | $87 |
| Teva Pharmaceuticals USA, Inc. | 5 | $76 |
| Janssen Pharmaceuticals, Inc | 3 | $60 |
| Lundbeck LLC | 3 | $56 |
| Supernus Pharmaceuticals, Inc. | 3 | $48 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
Products named: VRAYLAR, INGREZZA, FANAPT, CAPLYTA, ARISTADA, REXULTI, Qelbree, UZEDY.
Industry payments across NJ — which companies pay providers there.
